Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MATCH results: implications for the internist.

Helmi L Lutsep1

  • 1Oregon Stroke Center and Department of Neurology, Oregon Health & Science University, Portland, Ore 97239-3098, USA. lutseph@ohsu.edu

The American Journal of Medicine
|June 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.

The Lancet. Neurology·2023
Same author

Endovascular Therapy for Basilar Artery Occlusion: Among the First to Conceptualize, Last to Prove.

Stroke·2023
Same author

Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2022
Same author

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis.

Neurology·2021
Same author

Global impact of COVID-19 on stroke care.

International journal of stroke : official journal of the International Stroke Society·2021
Same author

Prevalence of Retinal Emboli and Acute Retinal Artery Occlusion in Acute Ischemic Stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2019

Adding aspirin to clopidogrel did not significantly improve secondary stroke prevention in high-risk patients. The combination therapy also increased the risk of life-threatening bleeding complications.

Area of Science:

  • Cardiology
  • Neurology
  • Clinical Trials

Background:

  • Antiplatelet therapy is crucial for secondary stroke prevention.
  • Combination antiplatelet therapy has shown promise but requires careful evaluation.
  • Previous studies like ESPS-2 demonstrated benefits of combined therapy.

Purpose of the Study:

  • To evaluate the safety and efficacy of clopidogrel plus aspirin for secondary stroke prevention.
  • To assess the benefit of dual antiplatelet therapy in high-risk patients with recent transient ischemic attack (TIA) or ischemic stroke.

Main Methods:

  • The Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study was a large-scale clinical trial.
  • Patients with recent TIA or ischemic stroke were treated with clopidogrel alone or clopidogrel plus aspirin.

Related Experiment Videos

Main Results:

  • Adding aspirin to clopidogrel did not provide a statistically significant greater reduction in stroke risk compared to clopidogrel monotherapy.
  • The combination therapy was associated with a significant increase in life-threatening bleeding complications.
  • The MATCH study did not replicate the positive findings of ESPS-2 regarding dual antiplatelet therapy.

Conclusions:

  • Clopidogrel plus aspirin is not recommended for secondary stroke prevention in patients with a history of ischemic stroke or TIA at this time.
  • The increased risk of severe bleeding outweighs the potential modest benefit in this patient population.
  • Further research may be needed to identify optimal antiplatelet strategies for high-risk stroke patients.